

Your Keywords

In addition to the RoboPICO highlighting, you can custom-add Your Keywords to have them underlined in the Abstract view.


User Keywords can be added or edited in **two places**; the list of User Keywords can be populated and edited from the Configure Screening page, and then additionally populated and edited from the Abstract View for any study within a nest.

Steps for Configuring Keyword Underlining

On the Configure Screening page


1. Go to the Configure Screening page

This is right below the “Screening” header in the AutoLit menu (see below).



2. Add Keywords to the “Your Keywords” Section

Click on “Your Keywords” in the toggle button next to Exclusion Reasons (see below). To add an exclusion reason click the “Add” button, type in your Keyword of interest and hit enter or add.



After adding a keyword, you can color code it by clicking the circle to the left of the keyword and choosing from the colors displayed. This color corresponds to the highlight color when that specific keyword is identified in an Abstract during Screening. If no color is chosen, the default is light blue.

Close X

Exclusion ReasonsYour Keywords

Add +

Keyword	
Description	
Summary	

Below you can see how this looks in an Abstract during Screening.

100Smith, 2022

AbstractFull TextSupplementsRelated Reports

CT.gov

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Brief **Summary**: The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria Detailed **Description**: The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Spontaneous Urticaria. There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab. Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase. Study Type: Interventional Actual Enrollment: 168 participants Status (as of import): Recruiting

☒ Population/Problem

☐ Intervention

☐ Outcome

☒ Your Keywords

3. Delete Your Keywords

If you need to delete a Keyword after creation, you can do so by selecting the trash can icon.

Deletion of the Keywords you created on this page can also be deleted from the Abstract view.

On the Abstract View

1. Go to the Abstract View in Screening

You can also add keywords during the screening process. Whenever you come across an abstract to screen, whether in the Screening module or Study Inspector, you can add keywords on the fly.

2. Click on “Your Keywords”

100

Smith, 2022

Abstract

Full Text

Supplements

Related Reports

CT.gov

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Brief Summary: The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria. **Detailed Description:** The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Spontaneous Urticaria. There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab. Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase. **Study Type:** Interventional **Actual Enrollment:** 168 participants **Status (as of import):** Recruiting

Population/Problem

Intervention

Outcome

Your Keywords

3. Type in desired keyword and hit “Add.”

A modal opens with the same functions as in Configure Screening as described above including color coding and ability to edit and delete existing keywords.

Abstract

Full Text

Supplements

Related Reports

Close X

Your Keywords

New keyword

Add +

Keyword	
<div></div> Description	<div></div>
<div></div> Summary	<div></div>
<div></div>	
<div></div>	
<div></div>	
<div></div>	
<div></div>	
<div></div>	
<div></div>	

Close

4. Any changes made here will be reflected in the abstract.

From:

<https://wiki.nested-knowledge.com/> - Nested Knowledge

Permanent link:

<https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:screening:keywords&rev=1701793518>

Last update: 2023/12/05 16:25